Alpine Immune Sciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $12.24
- Today's High:
- $13.13
- Open Price:
- $12.9
- 52W Low:
- $4.82
- 52W High:
- $10.3
- Prev. Close:
- $12.85
- Volume:
- 140209
Company Statistics
- Market Cap.:
- $375.58 million
- Book Value:
- 4.136
- Revenue TTM:
- $31.82 million
- Operating Margin TTM:
- -167.06%
- Gross Profit TTM:
- $-35299000
- Profit Margin:
- -169.92%
- Return on Assets TTM:
- -12.65%
- Return on Equity TTM:
- -35.47%
Company Profile
Alpine Immune Sciences Inc had its IPO on 2015-06-17 under the ticker symbol ALPN.
The company operates in the Healthcare sector and Biotechnology industry. Alpine Immune Sciences Inc has a staff strength of 85 employees.
Stock update
Shares of Alpine Immune Sciences Inc opened at $12.9 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $12.24 - $13.13, and closed at $12.28.
This is a -4.44% slip from the previous day's closing price.
A total volume of 140,209 shares were traded at the close of the day’s session.
In the last one week, shares of Alpine Immune Sciences Inc have slipped by -4.81%.
Alpine Immune Sciences Inc's Key Ratios
Alpine Immune Sciences Inc has a market cap of $375.58 million, indicating a price to book ratio of 1.5237 and a price to sales ratio of 9.423.
In the last 12-months Alpine Immune Sciences Inc’s revenue was $31.82 million with a gross profit of $-35299000 and an EBITDA of $-52564000. The EBITDA ratio measures Alpine Immune Sciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Alpine Immune Sciences Inc’s operating margin was -167.06% while its return on assets stood at -12.65% with a return of equity of -35.47%.
In Q3, Alpine Immune Sciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 1.7%.
Alpine Immune Sciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.76 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alpine Immune Sciences Inc’s profitability.
Alpine Immune Sciences Inc stock is trading at a EV to sales ratio of 1.3846 and a EV to EBITDA ratio of -0.8567. Its price to sales ratio in the trailing 12-months stood at 9.423.
Alpine Immune Sciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $291.60 million
- Total Liabilities
- $68.46 million
- Operating Cash Flow
- $25.79 million
- Capital Expenditure
- $55000
- Dividend Payout Ratio
- 0%
Alpine Immune Sciences Inc ended 2024 with $291.60 million in total assets and $0 in total liabilities. Its intangible assets were valued at $291.60 million while shareholder equity stood at $182.01 million.
Alpine Immune Sciences Inc ended 2024 with $0 in deferred long-term liabilities, $68.46 million in other current liabilities, 44000.00 in common stock, $-205097000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $126.63 million and cash and short-term investments were $248.86 million. The company’s total short-term debt was $5,265,000 while long-term debt stood at $0.
Alpine Immune Sciences Inc’s total current assets stands at $253.24 million while long-term investments were $28.02 million and short-term investments were $122.24 million. Its net receivables were $677000.00 compared to accounts payable of $3.24 million and inventory worth $0.
In 2024, Alpine Immune Sciences Inc's operating cash flow was $25.79 million while its capital expenditure stood at $55000.
Comparatively, Alpine Immune Sciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $12.28
- 52-Week High
- $10.3
- 52-Week Low
- $4.82
- Analyst Target Price
- $14.4
Alpine Immune Sciences Inc stock is currently trading at $12.28 per share. It touched a 52-week high of $10.3 and a 52-week low of $10.3. Analysts tracking the stock have a 12-month average target price of $14.4.
Its 50-day moving average was $12.42 and 200-day moving average was $9.21 The short ratio stood at 9.15 indicating a short percent outstanding of 0%.
Around 668.4% of the company’s stock are held by insiders while 8954.5% are held by institutions.
Frequently Asked Questions About Alpine Immune Sciences Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.